Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReneuRx in Lateral Hip Pain
NCT07568015Recruiting
- Sponsor
- Brixton Biosciences
- Start
- Jul 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Randomised trial in greater trochanteric pain syndrome (GTPS) (2 arms), sponsored by Brixton Biosciences. Primary endpoints: Primary Effectiveness at 3 months and Primary Safety at 12 months. Started Jul 2026; status: recruiting.
02
Conditions
greater trochanteric pain syndrome (GTPS)
Beyond the preview
Go deeper on NCT07568015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568015.